BridgeBio Pharma, Inc. — Director's Dealing 2022

Nov 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2022-11-16

Reporting Person: HOMCY CHARLES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-16	Common Stock	M	3760	—	Acquired	1215552	Direct
2022-11-16	Common Stock	F	1301	$9.64	Disposed	1214251	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-16	Restricted Stock Units	$	M	3760	Disposed		Common Stock (3760)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Includes 840 shares acquired on February 17, 2021 and 1,497 shares acquired on August 15, 2022 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs.

F4: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.